Epigenetic profiling joins personalized cancer medicine

Expert Review of Molecular Diagnostics

Volumn 13, Issue 5, 2013, Pages 473-479

  Heyn, Holger ^a   Méndez González, Jesús ^a   Esteller, Manel ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

alkylating agents; biomarker; DNA methylation; epigenetics; glioma; MGMT; patient stratification; personalized medicine; targeted therapy

Indexed keywords

DNA; HISTONE; TUMOR MARKER; XENOBIOTIC AGENT;

APOPTOSIS; CANCER THERAPY; DETOXIFICATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE EXPRESSION PROFILING; HISTONE MODIFICATION; HUMAN; ONCOLOGY; PERSONALIZED MEDICINE; REVIEW; SIGNAL TRANSDUCTION;

BIOMARKERS, PHARMACOLOGICAL; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879386848     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.36     Document Type: Review

References (78)

1. Ong FS, Das K, Wang J et al. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev. Mol. Diagn. 12(6), 593-602 (2012).
2. Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat. Rev. Clin. Oncol. 9(9), 520-528 (2012).
3. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2010).
4. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11(10), 726-734 (2011).
5. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
7. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13(10), 679-692 (2012).
8. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011).
9. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19), 1350-1354 (2000).
10. Weber M, Davies JJ, Wittig D et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37(8), 853-862 (2005).
11. Weber M, Hellmann I, Stadler MB et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39(4), 457-466 (2007).
12. Molaro A, Hodges E, Fang F et al. Sperm methylation profiles reveal features of epigenetic inheritance and evolution in primates. Cell 146(6), 1029-1041 (2011).
13. Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43(8), 768-775 (2011).
14. Bock C, Beerman I, Lien WH et al. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol. Cell 47(4), 633-647 (2012).
15. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
16. Williams K, Christensen J, Pedersen MT et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473(7347), 343-348 (2011).
17. Branco MR, Ficz G, Reik W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat. Rev. Genet. 13(1), 7-13 (2012).
18. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
19. Xie W, Barr CL, Kim A et al. Baseresolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome. Cell 148(4), 816-831 (2012).
20. Ziller MJ, Müller F, Liao J et al. Genomic distribution and inter-sample variation of nonCpG methylation across human cell types. PLoS Genet. 7(12), e1002389 (2011).
21. Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010).
22. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
23. Ernst J, Kheradpour P, Mikkelsen TS et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473(7345), 43-49 (2011).
24. Chodavarapu RK, Feng S, Bernatavichute YV et al. Relationship between nucleosome positioning and DNA methylation. Nature 466(7304), 388-392 (2010).
25. Esteller M. Noncoding RNAs in human disease. Nat. Rev. Genet. 12(12), 861-874 (2011).
26. Harris RA, Wang T, Coarfa C et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat. Biotechnol. 28(10), 1097-1105 (2010).
27. Beyan H, Down TA, Ramagopalan SV et al. Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. Genome Res. 22(11), 2138-2145 (2012).
28. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat. Protoc. 6(4), 468-481 (2011).
29. Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. U.S.A. 89(5), 1827-1831 (1992).
30. Lister R, O'Malley RC, Tonti-Filippini J et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133(3), 523-536 (2008).
31. Li Y, Zhu J, Tian G et al. The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol. 8(11), e1000533 (2010).
32. Heyn H, Li N, Ferreira HJ et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl Acad. Sci. USA 109(26), 10522-10527 (2012).
33. Hon GC, Hawkins RD, Caballero OL et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22(2), 246-258 (2011).
34. Berman BP, Weisenberger DJ, Aman JF et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44(1), 40-46 (2012).
35. Kulis M, Heath S, Bibikova M et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44(11), 1236-1242 (2012).
36. Heyn H, Vidal E, Sayols S et al. Wholegenome bisulfite DNA sequencing of a DNMT3B mutant patient. Epigenetics 7(6), 542-550 (2012).
37. Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with single CpG site resolution. Genomics 98(4), 288-295 (2011).
38. Bibikova M, Fan JB. GoldenGate assay for DNA methylation profiling. Methods Mol. Biol. 507, 149-163 (2009).
39. Sandoval J, Heyn H, Moran S et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6(6), 692-702 (2011).
40. Walter K, Holcomb T, Januario T et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin. Cancer. Res. 18(8), 2360-2373 (2012).
41. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
42. Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J. Neurooncol. 105(2), 325-335 (2011).
43. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59(4), 793-797 (1999).
44. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18(14), 2335-2341 (1999).
45. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2?-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60(21), 6039-6044 (2000).
46. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 100(5), 758-763 (2009).
47. Zeller C, Dai W, Steele NL et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31(42), 4567-4576 (2012).
48. Ivanova T, Zouridis H, Wu Y et al. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 62(1), 22-33 (2013).
49. Ibanez de Caceres I, Cortes-Sempere M, Moratilla C et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29(11), 1681-1690 (2010).
50. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92(7), 564-569 (2000).
51. Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7(11), 1225-1229 (2012).
52. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
53. Xu Y, Diao L, Chen Y et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann. Oncol. PMID:23406733 (2013) (Epub ahead of print).
54. Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer Invest. 27(8), 877-884 (2009).
55. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9(5), 568-574 (2003).
56. Veeck J, Ropero S, Setien F et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28(29), e563-564; author reply e565 (2010).
57. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
58. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
59. Agrelo R, Cheng WH, Setien F et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23), 8822-8827 (2006).
60. Chen HY, Shao CJ, Chen FR, Kwan AL, Chen ZP. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 126(8), 1944-1954 (2010).
61. Sabatino MA, Marabese M, Ganzinelli M, Caiola E, Geroni C, Broggini M. Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol. Cancer 9, 259 (2010).
62. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate 72(11), 1248-1261 (2011).
63. Dejeux E, Rønneberg JA, Solvang H et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 9, 68 (2010).
64. Cho YH, Shen J, Gammon MD et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res. Treat. 131(1), 197-205 (2012).
65. Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res. Treat. 100(2), 169-176 (2006).
66. Chekhun VF, Kulik GI, Yurchenko OV et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett. 231(1), 87-93 (2006).
67. Shen L, Kondo Y, Ahmed S et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 67(23), 11335-11343 (2007).
68. Soengas MS, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409(6817), 207-211 (2001).
69. Iorns E, Turner NC, Elliott R et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13(2), 91-104 (2008).
70. Maier S, Nimmrich I, Koenig T et al.; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, nodenegative breast cancer patients-Technical and clinical validation in a multicentre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur. J. Cancer 43(11), 1679-1686 (2007).
71. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12(18), 5268-5272 (2006).
72. Koga T, Takeshita M, Yano T, Maehara Y, Sueishi K. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Int. J. Cancer 128(5), 1009-1017 (2011).
73. Salazar F, Molina MA, Sanchez-Ronco M et al. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 72(1), 84-91 (2011).
74. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 14(1), 202 (2012).
75. Barretina J, Caponigro G, Stransky N et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603-607 (2012).
76. Garnett MJ, Edelman EJ, Heidorn SJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391), 570-575 (2012).
77. Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390), 479-483 (2012).
78. Sandoval J, Heyn H, Méndez-González J et al. Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 160(3), 406-409 (2013).